Linked Life Data

20920933

Source:http://linkedlifedata.com/resource/pubmed/id/20920933

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-10-5
pubmed:abstractText
Subarachnoid hemorrhage (SAH) has a worldwide incidence of approximately 10.5 cases per 100,000 person-years and constitutes 3% of all strokes. Erythropoietin (EPO) has recently been proposed for the treatment of a variety of brain diseases, including SAH, because of its neuroprotective effects. Hence, the current evidence in the published literature was reviewed to determine the potential utility of EPO in the treatment of SAH.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1878-8750
pubmed:author
pubmed:copyrightInfo
Copyright © 2010 Elsevier Inc. All rights reserved.
pubmed:issnType
Print
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
500-7
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Erythropoietin for the treatment of subarachnoid hemorrhage: a review.
pubmed:affiliation
Department of Neurological Surgery, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA.
pubmed:publicationType
Journal Article, Review